December 9, 2022 – announcement no. 12
Shares received as a result of automatic reinvestment of dividends under short-term and long-term share-based incentive programs in Chr. Hansen Holding A/S administered by a third party.
Please see attachment.
For further information please contact:
Anders Mohr Christensen, Vice President Group Strategy & Investor Relations, Tel: +45 2515 2364
Cristina Rønde Hefting, Senior Investor Relations Manager, Tel: +45 4072 1224
Kathrine Westermann, Head of Media Relations, Tel: +45 2381 5595
Upcoming Life Sciences Events
- March 2023
- Basel: BIO-Europe Spring® 2023
- Zurich: Swiss Nordic Bio 2023
- April 2023
- Basel: Swiss Biotech Day 2023
Latest company news
GHIT Fund Announces New Investments: A Total of Approximately 260 Million Yen in Shionogi, Takeda Pharmaceutical for New Malaria Drug Development
Publication of exemption document in relation to the proposed combination of Chr. Hansen and Novozymes, confirmation of outlook for 2022/23 and proposed candidates to the Board of Directors of the combined company